APEX1 and neoplasm: In xenograft mice injected subcutaneously with CCSCs, intratumoral administration of APX3330 increases tumor response to 5-FU delivered intraperitoneally.179 This indicates that APX3330 could potentiate other colon cancer treatments by inhibiting Ref-1/APE1’s crucial redox activity.